

Prior Authorization Workflow-to-Standards Task Group Update

Tony Schueth Task Group Leader

National Committee on Vital and Health Statistics Subcommittee on Standards & Security

December 7, 2005



Task Group Overview

- Task Group Name:
 - Prior Authorization Workflow-to-Transactions
- Date Task Group Formed:
 - November 18, 2004
- Task Group Leader:
 - Tony Schueth, MS
- Objectives:
 - Identify the standards required to support ePrescribing the electronic delivery of PA-related transactions
 - Understand PA work flow in the physician office, plan and pharmacy



Philosophy

"... this is not an attempt to usurp the coverage decisions of the plans but an effort to streamline and standardize the mechanism for the activity."

> - NCPDP Prior Authorization Workflow-to-Transactions Task Group Member



Task Group Members

| Name | Company | | |
|-----------------------|------------------------|--|--|
| Alan Smith | ProxyMed | | |
| Andy Fontalbert | ACS | | |
| Avi Erlich | Wellpoint | | |
| Barbara McKinnon | Point-of-Care Partners | | |
| Barbara Hollerung | MN Medicaid | | |
| Brandon Brylawski, MD | DrFirst | | |
| Brian Bamberger | MediMedia | | |
| Carolyn Gingras, MS | Lifespan | | |
| Cody Wibert | State of Minn. | | |
| Colin Halloran | Express Scripts | | |
| Dan Makowski, RPh | Allscripts | | |
| Darlene Rocco, RPh | Excellus | | |
| Jeff Mays | MediMedia | | |
| John Klimek, RPh | Albertsons | | |
| Kathy Finley | Argus | | |
| Keith Faigin | EHIM | | |
| Lynne Gilbertson | NCPDP | | |
| Margaret Weiker | EDS | | |
| Mark Gruenhaupt | Argus | | |

| Name | Company | | | |
|----------------------------|-----------------------|--|--|--|
| Michael Van Orum, RN, ,RPH | American Home Patient | | | |
| Nancy Nemes | WebMD | | | |
| Ned Hanson | HealthNet | | | |
| Peter Kaufman, MD | DrFirst | | | |
| Shelly Spiro, RPh | Consultant | | | |
| Reid Coleman, MD | Lifespan | | | |
| Richard Stefanicci | USIP | | | |
| Rohit Nayak | MedPlus | | | |
| Ross Martin, MD | Pfizer | | | |
| Sandra Ebel | X12 | | | |
| Sherry Neuman | Consultant | | | |
| Spencer Rylander | Lifespan | | | |
| Stacey Barber | EDS, X12 | | | |
| Steve Waldren, MD | AAFP | | | |
| Stuart Kersky, RPh | Walgreens | | | |
| Sue Thompson | West VA Medicaid, HL7 | | | |
| Terry Torgler | Argus | | | |
| Teri Byrne | RxHub | | | |
| Tim McNeil | RxHub 4 | | | |



Definitions

- Status a designation indicating whether a medication requires prior authorization
- Criteria systematically developed statements that can be used to assess appropriateness.
- *Rule* code or set of codes governing action or procedure.



Sample PA Form - Celebrex



CONTAINS CONFIDENTIAL PATIENT INFORMATION Celebrex (celecoxib) Prior Authorization of Benefits (PAB) Form

Complete form in its entirety and fax to: Prior Authorization of Benefits (PAB) Center at (888) 831-2243

1. PATIENT INFORMATION

2. PHYSICIAN INFORMATION

| Patient Name: | Prescribing Physician: |
|-----------------------------|------------------------|
| Patient ID #: | Physician Specialty: |
| Patient DOB: | Physician DEA#: |
| Date of Rx: | Physician Phone#: |
| Patient is: 🛛 Female 🗳 Male | Physician Fax#: |

3. INDICATE DIAGNOSIS

| Diagnosis: | th: Celebrex 200mg Celebrex I 100mg Celebrex 200mg Celebrex 400mg Celebrex 400mg Celebrex 400mg 60 per 30 days 0 200mg 11 per 30 days 60 per 30 days | | | | |
|----------------|--|--------------------|-------|---|--|
| Strength: | Celebrex 200mg | 1 | | | Familial Adenomatous Polyposis Celebrex 400mg |
| Max Qty Limit: | 30 per 30 days | 60 per 30 days 📮 2 | 200mg | | 0 |
| | OA or RA: Must meet criteria below in | | | Must be female and meet criteria | Only diagnosis required |
| | 4A <u>OR </u> 4B <u>OR</u> 4C | | | below in 4A <u>OR</u> both 4B <u>AND</u> 4C | |



Sample PA – Celebrex cont.


4. APPROVAL CRITERIA: CHECK ALL BOXES THAT APPLY

Any areas that are not filled out will be considered not applicable to your patient AND MAY AFFECT THE OUTCOME OF THIS REQUEST

| A. 🗆 | Yes | | No | Patient has major NSAID-induced GI complication risk factors: ONE OF THE FOLLOWING MUST BE PRESENT |
|--|---|------|---|---|
| | Yes | | No | Active non-menstrual bleeding or bleeding disorder |
| | Yes | | No | Concurrent anticoagulation therapy Please note: bleeding events and increased prothrombin time have been reported in |
| | | | | patients taking COX-II Selective NSAIDs concurrently with warfarin. INR monitoring is still necessary in COX-IIs. |
| | Yes | | No | Patient has previous documented history of NSAID-induced gastropathy |
| в. 🗆 | Yes | | No | Patient has other NSAID-induced GI complication risk factors: TWO OR MORE OF THE FOLLOWING MUST BE PRESENT |
| | Yes | | No | Age ≥ 65 years old |
| | Yes | | No | Chronic major organ impairment (please specify) or active Rheumatoid Arthritis |
| | Yes | | No | Concomitant chronic systemic corticosteroid therapy |
| | Yes | | No | Chronic high-dose NSAID therapy (e.g. 2-3 times the standard dose to achieve therapeutic effect) |
| | Yes | | No | Anti-platelet agents for vascular prophylaxis |
| - | | | No | Patient has documented trial and failure of 2 or more prescription-strength NSAIDs |
| С. 🗆 | Yes | - | 110 | (Must specify trials below) |
| | Yes | | | |
| NSA | | | | (Must specify trials below) NSAID #2: |
| NSA 5. PH | ID #1: | N SI | GNA | (Must specify trials below) NSAID #2: TURE |
| NSA 5. PH Prescri | ID #1: | N SI | GNA zed Sig | (Must specify trials below) NSAID #2: TURE |
| NSA 5. PH Prescri Prior Au medicat | ID #1: (SICIA Der or Au thorization ons are a TANT W ntial, the | N SI | GNA zed Sig mefits is riate for a ING: TI | (Must specify trials below) NSAID #2: FURE nature nature not the practice of medicine or the substitute for the independent medical judgment of a treating physician, only a treating physician can determine what |



What is the proposed workflow? (Feasible for CMS eRx pilots)





Task Group Accomplishments

- Mapped ambulatory PA workflow
- Leveraged AHRQ grant to complete analysis of PA forms
- Analyzed 350 forms / 1,750 questions / 53 payers
- Created database to support analysis of industry forms
- Leveraged additional AHRQ grant to normalize data in the following therapeutic categories:
 - Erectile Dysfunction
 - Growth Hormones

- AntiFungals
- NSAIDs/Cox2s

– PPIs

- Opoid Agonists

- Unspecified
- Formed separate task group to address PA in Longterm Care
- Mapped Long-term Care PA workflow



Timeline

| | 2005 | | | 20 | 06 | | |
|---------|--|--|---|--|--|---|--|
| | 12/05 | 1/06 | 2/06 | 3/06 | 4/06 | 5/06 | 6/06 |
| PHASE 1 | | Present PA Progress at HL7 Conference | Present PA Progress at X12N Conference | | | Present PA Progress at HL7 Conference | Present PA Progress at X12N Conference |
| | X12N 278 - 5010 "public comments" reconciled | | X12N 278 - 5010 Vote to Publish | X12N Technical Assessment | Publish 5010 Guide Published | | |
| | X12N 275-5010 Post for "public comment" | Review Imp Guide at 1/06 conference | | Reconcile "public comments" | | | Reconcile "public comments" at 6/06 conference |
| | HL7 PA Attachment Post for "public comment" | Announce Ballot | Post for Ballot | Open Ballot" | Close Ballot | Reconcile "public comments" at 5/06 conference | |
| PHASE 2 | Planning for analysis of add'l 11 PA criteria categories | Normalize additional PA criteria | Normalize additional PA criteria | Normalize additional PA criteria | Normalize additional PA criteria | Review impact of add'I PA criteria on standards | |



Next Steps

- HL7 ballot of the PA Attachment
- Pilot Test
- Complete PA data normalization for remaining 11 therapeutic categories (?)
- Long-term care needs to determine the impact of PA to them, and how to streamline their processes